The Pharmaceutical & Biotechnology industry is busy closing plants, trimming staffs, capturing efficiencies from recent mergers -- and building new facilities! As insurance companies' reimbursement policies exert more and more control over the Pharma & Biotech industry, the industry is looking at a barbell-shaped future: low-cost generic drugs, at the one end, and high-cost "biologicals," on the other. There is no longer any "middle" between the two extremes. Annette Kreuger, IIR's vice president of research for the Pharmaceutical and Biotechnology industry, explains why this future could be profitable for companies that supply equipment and services to this industry.